NCT06552572View on ClinicalTrials.gov

Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2028

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Glofitamab

Glofitamab is administered to patients who have residual disease after CD19 CAR T-cell therapy for their relapsed or refractory diffuse large B-cell lymphoma

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT06552572 - Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy | Biotech Hunter | Biotech Hunter